Modeling drug dosing for obese children
Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity
This study is working to find the best ways to dose medications for children with obesity by using special math models that take into account how their bodies process drugs differently, so they can get the safest and most effective treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10456301 on NIH RePORTER |
What this research studies
This research focuses on improving drug dosing for children with obesity by using advanced mathematical models that account for their unique physiological and body composition changes. It aims to develop physiologically-based pharmacokinetic (PBPK) models that predict how drugs behave in the bodies of obese children, which can differ significantly from those of non-obese children. By analyzing data from various drugs commonly prescribed to this population, the study seeks to optimize dosing recommendations, ensuring that children receive the most effective and safe medication. The approach involves both retrospective analysis of existing data and prospective modeling for additional drugs.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-21 years who are classified as obese and require medication.
Not a fit: Patients who are not obese or those who do not require medication may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective drug dosing for obese children, improving their treatment outcomes.
How similar studies have performed: Previous research has shown promise in using pharmacokinetic modeling for drug dosing, suggesting that this approach could yield significant advancements in pediatric care.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Dumond, Julie Brumer — Univ of North Carolina Chapel Hill
- Study coordinator: Dumond, Julie Brumer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.